[Dose-effects and chemotherapy dose intensity of aggressive non-Hodgkin's lymphomas in the adult].
The CHOP regimen (cyclophosphamide vincristine, adriamycin, prednisone) is considered since twenty years as the standard treatment of disseminated aggressive non-Hodgkin's lymphomas and cures approximately 30% of patients. More recently, intensive chemo(radio)therapy followed by rescue with bone marrow or blood hematopoietic stem cells has become the standard treatment of chemosensitive relapses of aggressive non-Hodgkin's lymphomas. Consequently, two questions with practical applications have arisen and are discussed in this review: Is it justified to increase the dose intensity of chemotherapy, using either single treatment intensification with stem-cell rescue, or sequential intensified chemotherapies, especially in cases with adverse prognostic factors? On the contrary, is a decrease in treatment intensity compared to CHOP chemotherapy, especially in elderly patients, harmful to the patient?
Solal-Céligny
P
P
Centre J.-Bernard, Le Mans, France.
Colombat
P
P
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D018579:Patient Selection; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone